Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 776 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... July 16, 2025 Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... June 7, 2023 Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer January 6, 2021 Embedding research integrity at the core of our science July 28, 2021 Load more HOT NEWS 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... Embrace Your Inner Flexibility Alternatives for Outdoor Foods Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk...
